Prominent neuroleptic sensitivity in a case of early-onset alzheimer disease due to presenilin-1 G206A mutation

Cognitive and Behavioral Neurology

Volumn 21, Issue 3, 2008, Pages 190-195

  Cercy, Steven P ^a,b,c,e   Sadowski, Martin J ^a,d   Wisniewski, Thomas ^c,d  

^a Memory Disorders Clinic   (United States)

^b Mental Health ^*  (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Extrapyramidal signs; Neuroleptic sensitivity; Presenilin 1

Indexed keywords

ALANINE; DONEPEZIL; GLYCINE; MEMANTINE; NEUROLEPTIC AGENT; PRESENILIN 1; RISPERIDONE;

ADULT; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CENTRAL AMERICA; CLINICAL EVALUATION; COGNITIVE DEFECT; DELUSIONAL DISORDER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GENE; HETEROZYGOSITY; HUMAN; LABORATORY TEST; MALE; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; ORTHOSTATIC HYPOTENSION; PHENOTYPE; POINT MUTATION; PRESENILIN 1 G206A GENE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SYNCOPE; CHEMICALLY INDUCED DISORDER; DRUG HYPERSENSITIVITY; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PEDIGREE;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DNA MUTATIONAL ANALYSIS; DRUG HYPERSENSITIVITY; HUMANS; MALE; MIDDLE AGED; PEDIGREE; POINT MUTATION; PRESENILIN-1;

EID: 62249141783     PISSN: 15433633     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNN.0b013e31817d74bf     Document Type: Article

References (40)

1. Rippon GA, Crook R, Baker M, et al. Presenilin 1 mutation in an African American family with atypical Alzheimer disease. Arch Neurol. 2003;60:884-888.
2. Moonis M, Swearer JM, Dayaw MPE, et al. Familial Alzheimer disease: decreases in CSF Ap42 levels precede cognitive decline. Neurology. 2005;65:323-325.
3. Athan ES, Williamson J, Ciappa A, et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA. 2001;286:2257-2263.
4. Janssen JC, Hall M, Fox NC, et al. Alzheimer's disease due to intronic presenilin 1 (PSEN1 intron 4) mutation. Brain. 2000;123:894-907.
5. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease:prospective analyses from the Predictors Study. Neurology.1994;44:2300-2307.
6. Yokota O, Terada S, Ishizu H, et al. NACP/a-synuclein, NAC, b-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases. Acta Neuropathol. 2002;104:637-648.
7. Jimenez-Escrig A, Rabano A, Guerrero C, et al. New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism. Eur J Neurol. 2004;11:663-669.
8. Ishikawa A, Piao Y-S, Miyashita A, et al. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann Neurol. 2005;57:429-434.
9. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry. 2005;66:633-637.
10. Ballard C, Grace J, McKeith I, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet. 1998;351:1033.
11. Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug- induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharm. 1999;19:322-328.
12. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863-1872.
13. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2:605-613.
14. Wada-Isoe K, Kitayama M, Nakaso K, et al. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci. 2007;260:33-37.
15. Tsuang D, Simpson K, Larson EB, et al. Predicting Lewy body pathology in a community-based sample with clinical diagnosis of Alzheimer's disease. J Geriatr Psychiatry Neurol. 2006;19:195-201.
16. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropatho- logical review of 145 cases using alpha-synuclein immunochemistry.Brain Pathol. 2000;10:378-384.
17. Rosenberg CK, Pericak-Vance MA, Saunders AM, et al. Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP17 gene mutation. Acta Neuropathol (Berl). 2000;100:145-152.
18. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;60:1586-1590.
19. Tsuang DW, Wilson RK, Lopez OL, et al. Genetic association between the APOE 4 allele and Lewy bodies in Alzheimer disease. Neurology. 2005;64:509-513.
20. Wirths O, Bayer TA. a-synuclein, Ab and Alzheimer's disease. Prog Neuropsychopharm Biol Psychiatry. 2003;27:103-108.
21. Hardy J. Pathways to primary neurodegenerative disease. Mayo Clinic Proc. 1999;74:835-837.
22. Goldman JS, Reed B, Gearhart R, et al. Very early-onset familial Alzheimer's disease: a novel presenilin 1 mutation. Int J Geriatr Psychiatry. 2002;17:649-651.
23. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain. 1999;122:1449-1468.
24. Piggott MA, Perry EK, Marshall EF, et al. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. Biol Psychiatry. 1998;44:765-774.
25. Sweet RA, Hamilton RL, Healy MT, et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol.2001;58:466-472.
26. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of Risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988;247:661-670.
27. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466-476.
28. Naber D, Greenspan A, Schreiner A. Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial. Psycho- pharmacology. 2007;191:1027-1029.
29. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174-6184.
30. Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci. 1995;15:821-829.
31. Mamo DC, Sweet RA, Mulsant BH, et al. Effect of Nortriptyline and Paroxetine on extrapyramidal signs and symptoms. Am JGeriatr Psychiatry. 2000;8:226-231.
32. Volkow ND, Wang GJ, Maynard L, et al. Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: a preliminarystudy. Psychiatry Res. 2002;116:163-172.
33. Hedenmalm K, Guzey C, Dahl ML, et al. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharm. 2006;26:192-197.
34. Martinez D, Broft A, Foltin RW, et al. Cocaine dependence and D2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behaviour. Neuropsychopharma- cology. 2004;29:1190-1202.
35. Potvin S, Pampoulova T, Mancini-Marie A, et al. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry.2006;77:796-798.
36. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer's disease. Neurology. 2000;54:1965-1971.
37. Sweet RA, Nimgaonkar VL, Kamboh MI, et al. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol. 1998;55:1335-1340.
38. Holmes C, Smith H, Ganderton R, et al. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation.J Neurol Neurosurg Psychiatry. 2001;71:777-779.
39. Holmes C, Arranz MJ, Powell JF, et al. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet. 1998;7:1507-1509.
40. Zdanys KF, Kleiman TG, MacAvoy MG, et al. Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. Neuropsychopharmacology. 2007;32:171-179.